List of Excipients in Branded Drug AUVELITY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Axsome Therapeutics Inc	AUVELITY	dextromethorphan hydrobromide, bupropion hydrochloride	81968-045	CARBOMER HOMOPOLYMER TYPE	2043-01-20
Axsome Therapeutics Inc	AUVELITY	dextromethorphan hydrobromide, bupropion hydrochloride	81968-045	CELLULOSE, MICROCRYSTALLINE	2043-01-20
Axsome Therapeutics Inc	AUVELITY	dextromethorphan hydrobromide, bupropion hydrochloride	81968-045	CROSPOVIDONE	2043-01-20
Axsome Therapeutics Inc	AUVELITY	dextromethorphan hydrobromide, bupropion hydrochloride	81968-045	CYSTEINE HYDROCHLORIDE	2043-01-20
Axsome Therapeutics Inc	AUVELITY	dextromethorphan hydrobromide, bupropion hydrochloride	81968-045	FERRIC OXIDE RED	2043-01-20
Axsome Therapeutics Inc	AUVELITY	dextromethorphan hydrobromide, bupropion hydrochloride	81968-045	FERRIC OXIDE YELLOW	2043-01-20

Auvelity Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Auvelity is a fixed-dose, extended-release tablet combining dextromethorphan hydrobromide and bupropion hydrochloride. Its commercial differentiation depends primarily on pharmacokinetic interaction and controlled release, not on novel excipients. The core opportunity is to develop equivalent release, stability, manufacturability and dose-flexibility platforms around the combination.

Axsome Therapeutics markets Auvelity for major depressive disorder in adults. The FDA approved the product on Aug. 18, 2022, under NDA 214278.[1] Each tablet contains 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride.[2] Bupropion inhibits CYP2D6-mediated metabolism of dextromethorphan, increasing and prolonging dextromethorphan exposure.

What is Auvelity’s formulation and excipient strategy?

Auvelity uses a conventional oral tablet architecture with extended-release functionality. The FDA-approved product contains the following inactive ingredients:

Excipient	Likely formulation role
Microcrystalline cellulose	Diluent, compressibility and tablet structure
Crospovidone	Superdisintegrant and matrix-processing aid
Hypromellose	Release-control polymer and film-forming material
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-coating polymer
Polyethylene glycol	Plasticizer in the film coating
Sodium chloride	Osmotic or release-modifying component, depending on layer or matrix placement
Talc	Anti-tacking and coating-process aid
Titanium dioxide	Opacifier and colorant

The excipient list is consistent with a conventional, scalable tablet process rather than a highly specialized delivery platform.[2] The commercial value is concentrated in how these materials are arranged, processed and combined with the two active ingredients.

Why the excipients matter

The formulation must manage four technical constraints:

1. Bupropion must provide sustained exposure.
2. Dextromethorphan must achieve adequate exposure after CYP2D6 inhibition.
3. The tablet must remain physically and chemically stable during storage.
4. The two active ingredients must maintain content uniformity despite different dose levels and physicochemical properties.

The release-control polymer, tablet compaction profile, granulation method, particle-size distribution and coating process can affect dissolution. Those parameters may create practical barriers even where a generic developer uses the same inactive ingredients.

The excipient system also has to support a single-tablet regimen. Auvelity is administered initially as one tablet daily, with an increase to one tablet twice daily after three days when clinically appropriate.[2] A fixed-dose tablet reduces the need for separate dosing of dextromethorphan and bupropion and supports adherence.

What formulation patents protect Auvelity?

The commercial protection for Auvelity is likely to rely on a combination of composition, dosing, pharmacokinetic and method-of-use claims rather than on the identity of the excipients alone.

Relevant claim categories include:

• Fixed-dose combinations of dextromethorphan and bupropion.
• Sustained-release or extended-release delivery of bupropion.
• Dextromethorphan exposure achieved through CYP2D6 inhibition.
• Treatment of major depressive disorder with the combination.
• Dosing schedules using one or two tablets per day.
• Formulation processes that produce the approved dissolution profile.
• Stability and impurity-control methods.

The FDA Orange Book is the controlling source for patents and regulatory exclusivity listed against NDA 214278.[3] Patent scope should be assessed claim by claim. An excipient patent is commercially meaningful only if it covers a required formulation feature or manufacturing step that a generic cannot readily design around.

Are the excipients themselves strongly protected?

Usually, no. Microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate and common coating materials are established pharmaceutical excipients. A patent directed only to using those materials in generic proportions would have limited exclusionary value.

Stronger protection may arise from:

• Specific polymer ratios.
• Layered or multiparticulate release structures.
• Defined dissolution windows.
• Particle-size or solid-state limitations.
• Water-activity or moisture-control specifications.
• A manufacturing sequence required to achieve bioequivalence.
• Combination claims tied to dextromethorphan exposure and bupropion release.

The central competitive question is whether the claims require the exact approved excipient architecture or merely an equivalent pharmacokinetic result.

How does Auvelity’s excipient strategy support generic competition?

Auvelity is a small-molecule product, so future competition will proceed through abbreviated new drug applications rather than biosimilar applications. A generic developer will need to demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.[4]

The most practical generic strategies are:

Generic strategy	Commercial advantage	Technical risk
Copy the listed excipients	Simplifies development and reduces formulation risk	May encounter patent or process claims
Use a different release polymer	Creates a design-around pathway	Dissolution and bioequivalence risk
Use a different granulation process	May avoid manufacturing claims	Scale-up and content-uniformity risk
Develop a different coating system	Can reduce dependence on originator process	May alter release and stability
Match the reference dissolution profile	Improves regulatory predictability	May reproduce patented performance characteristics
Use alternative particle engineering	Can improve flow and blend uniformity	May affect exposure and tablet robustness

The most difficult attribute to replicate is not the presence of a particular excipient. It is the combined in vitro and in vivo performance of the formulation.

What manufacturing barriers exist?

Potential manufacturing barriers include:

• Maintaining uniform distribution of low-dose dextromethorphan relative to bupropion.
• Preventing segregation during blending and compression.
• Controlling bupropion release over the intended period.
• Limiting degradation and impurity formation.
• Managing coating weight and tablet moisture.
• Reproducing dissolution across commercial-scale batches.
• Controlling the interaction between granulation moisture and hypromellose performance.

These barriers favor contract manufacturers with established modified-release tablet capabilities. They also create opportunities for excipient suppliers offering directly compressible grades, engineered hypromellose, improved glidants and low-moisture coating systems.

What commercial opportunities exist for Auvelity excipients?

The largest near-term opportunity is not a proprietary Auvelity excipient. It is supply and formulation support for originator-scale production, generic development and lifecycle products.

Excipient supply opportunities

Potential supplier opportunities include:

• High-functionality microcrystalline cellulose for low-force compression.
• Engineered hypromellose grades with predictable hydration and release.
• Co-processed excipients that improve blend uniformity.
• Low-peroxide excipients to reduce oxidative degradation.
• Film-coating systems that reduce process time.
• Functional excipients supporting smaller or more robust tablets.
• Excipients with tighter particle-size specifications for content uniformity.

A supplier that demonstrates equivalent dissolution using fewer processing steps may create value for both Axsome and future generic manufacturers.

Reformulation opportunities

Lifecycle products could target:

• A lower-dose strength for titration.
• A once-daily presentation with longer bupropion release.
• A smaller tablet.
• A sprinkle formulation for patients with swallowing difficulty.
• An orally disintegrating or rapidly dispersing dosage form.
• A capsule or multiparticulate system.
• A modified tablet designed for improved gastrointestinal tolerability.
• A combination with a different antidepressant or augmentation agent.

Each reformulation would require a new regulatory and intellectual-property analysis. A lower-dose or once-daily product could expand prescribing flexibility but might also reduce tablet volume per patient and affect net pricing.

When does Auvelity lose exclusivity?

Auvelity’s exclusivity timeline has two separate components: FDA regulatory exclusivity and patent protection.

The product received approval for a new drug application in 2022. The FDA’s five-year new chemical entity exclusivity period generally protects the approved active moiety from submission of an ANDA or 505(b)(2) application for five years, subject to statutory exceptions.[5] That period is distinct from patent expiration and does not itself determine the earliest commercial generic launch date.

The likely commercial entry window depends on:

• Listed patent expiration dates.
• Patent-term adjustment.
• Patent-term extension, if granted.
• Pediatric exclusivity.
• Paragraph IV litigation.
• Settlement agreements.
• Generic approval timing.
• Regulatory exclusivity remaining at the time of filing.

A precise launch forecast requires the current Orange Book patent listing and litigation docket. The relevant practical rule is that a Paragraph IV certification can trigger litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman framework.[6]

What is the Orange Book status of Auvelity?

Auvelity is listed in the FDA Orange Book under NDA 214278.[3] The Orange Book identifies listed patents, pediatric exclusivity and related regulatory information. Because Orange Book listings can change through patent-listing updates, corrections, litigation outcomes and exclusivity changes, the record should be reviewed at the time of any investment, licensing or launch decision.

Auvelity is not a biologic and has no biosimilar pathway. Competitive entry will come from ANDA applicants or, for differentiated products, 505(b)(2) applicants.

Which companies are challenging Auvelity?

Public generic competition should be assessed through FDA ANDA activity, Paragraph IV litigation and commercial launch announcements. A complete competitive list depends on current FDA and court records.

The principal challenger categories are:

1. Generic pharmaceutical companies pursuing an ANDA for the fixed-dose extended-release tablet.
2. Specialty manufacturers developing alternative modified-release combinations.
3. 505(b)(2) sponsors pursuing different strengths, dosage forms or dosing schedules.
4. Excipient and contract-development organizations supporting bioequivalence programs.

No biosimilar competition is relevant because Auvelity contains chemically synthesized small molecules.

What generic entry risks exist?

The principal risks are:

• A successful Paragraph IV challenge to composition or use claims.
• A generic that designs around formulation claims while matching the clinical exposure profile.
• A 505(b)(2) product with a different dosage form or dosing schedule.
• Price erosion after multiple ANDA approvals.
• Therapeutic substitution if payers treat the combination as interchangeable with separate generic dextromethorphan and bupropion products.
• Prescriber switching after regulatory exclusivity expires.

Substitution with separate products is not necessarily clinically or commercially equivalent. Auvelity’s value includes the controlled interaction between bupropion and dextromethorphan, the approved dose regimen and the single-tablet format.

What patent litigation affects Auvelity?

Patent litigation risk will center on Paragraph IV certifications against Orange Book-listed patents. The most material disputes would involve:

• Whether a generic reproduces the claimed release profile.
• Whether a proposed label induces infringement of method-of-use claims.
• Whether the claims are valid and enforceable.
• Whether the generic has carved out patented indications.
• Whether a formulation change avoids infringement while remaining bioequivalent.

A method-of-use patent can remain commercially relevant even if a composition patent is invalidated, but its value depends on the ability to enforce the patented indication against the proposed generic label.

Settlement agreements may delay entry, permit an authorized generic, grant a license or establish a date-certain launch. Any settlement should be reviewed for entry date, product restrictions, manufacturing rights, royalty terms and Federal Trade Commission disclosure requirements.[7]

How strong is the Auvelity patent estate?

The estate is potentially strongest where formulation, pharmacokinetic interaction and clinical-use claims overlap. Its strength is lower if protection depends mainly on common excipients or broad combination claims vulnerable to prior-art challenges.

Protection layer	Relative strategic value
Fixed-dose combination	High if claim scope covers the commercial ratio and prior art is limited
Extended-release formulation	High if dissolution and process limitations are difficult to design around
CYP2D6-mediated exposure strategy	Moderate to high, depending on claim drafting and prior art
Major depressive disorder method of use	Moderate, subject to label-scarve-out issues
Common excipient composition	Low unless tied to specific performance limitations
Manufacturing process	Moderate if process is necessary for commercial-scale quality
New dosage form or strength	Potentially high for lifecycle management

The estate should be valued on enforceable claim scope, not patent count. A small number of overlapping, commercially relevant patents can provide stronger protection than a large portfolio of narrow process claims.

How does Auvelity compare with separate dextromethorphan and bupropion products?

Attribute	Auvelity	Separate products
Dosage form	Fixed-dose extended-release tablet	Separate products and schedules
Pharmacokinetic design	Intentional CYP2D6 inhibition	Interaction may be less consistently managed
Adherence	One combination regimen	Multiple products
Regulatory status	Approved combination for major depressive disorder	Individual products have separate indications
Generic substitution	Requires equivalent combination product	May involve therapeutic, not automatic, substitution
Excipient control	Integrated formulation	Depends on each product
Commercial differentiation	Combination, dosing and evidence	Lower unit cost may drive payer pressure

The commercial defense is strongest when the originator demonstrates clinical and adherence value beyond the availability of the two individual active ingredients.

What revenue exposure does Auvelity create?

Auvelity has become a central commercial product for Axsome. Axsome reported net product revenue for Auvelity in its SEC filings, with revenue growth driven by prescription expansion, payer coverage and commercial execution.[8]

Revenue exposure to generic entry depends on:

• The share of Axsome revenue generated by Auvelity.
• Net price after rebates.
• Number of approved generic competitors.
• Timing of first generic entry.
• Contracting with pharmacy benefit managers.
• Persistence of the product’s clinical differentiation.
• Expansion into additional indications or formulations.

A single first generic often causes less erosion than multiple competing products, but modified-release products can experience rapid price compression once several ANDAs are approved.

What licensing deals could create value around Auvelity?

Licensing opportunities fall into four categories:

Excipient and formulation licensing

A technology owner could license:

• A controlled-release polymer system.
• A moisture-resistant tablet platform.
• A low-dose blend-uniformity process.
• A smaller-tablet technology.
• A multiparticulate or sprinkle formulation.
• A coating process that improves scale-up.

Generic development licensing

Generic companies may seek rights to:

• Non-infringing formulation technology.
• Bioequivalence data packages.
• Manufacturing know-how.
• Alternative strengths or dosage forms.
• Authorized-generic supply arrangements.

Geographic licensing

Auvelity’s U.S. commercial rights may be separated from opportunities in Europe, Japan, Canada and emerging markets. Regulatory requirements for fixed-dose combinations, dextromethorphan scheduling, bupropion labeling and pharmacokinetic bridging will vary by jurisdiction.

Commercial partnerships

Potential structures include regional commercialization licenses, co-promotion, supply agreements and milestone-based formulation partnerships. The value of a geographic license will depend on local depression-market size, patent enforceability, controlled-substance rules and reimbursement.

Key Takeaways

• Auvelity is a dextromethorphan-bupropion extended-release tablet approved by the FDA in 2022.
• Its excipient system is conventional, but the release architecture and manufacturing process may be commercially difficult to reproduce.
• Common excipients are unlikely to provide meaningful protection by themselves.
• The strongest intellectual-property positions are likely to combine formulation, pharmacokinetic and method-of-use claims.
• Generic entry will occur through ANDAs, not biosimilars.
• Paragraph IV litigation, Orange Book listings and settlement terms will determine the practical launch window.
• The main excipient opportunities involve engineered release, blend uniformity, moisture control, coating efficiency and lifecycle reformulation.
• Auvelity’s commercial defense depends on the value of its single-tablet regimen and controlled pharmacokinetic interaction relative to separate dextromethorphan and bupropion products.

FAQs

Can a generic use different excipients from Auvelity?

Yes. An ANDA applicant can generally use different inactive ingredients if the product satisfies applicable FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality and labeling.

Is Auvelity a controlled-release or extended-release product?

Auvelity is an extended-release tablet. Its release profile is central to product performance and generic development.

Can a 505(b)(2) product compete with Auvelity?

Yes. A 505(b)(2) sponsor could pursue a different strength, dosage form, dosing schedule or formulation, subject to applicable patent and regulatory requirements.

Are dextromethorphan and bupropion combination products interchangeable with Auvelity?

Not automatically. Separate products may contain different release profiles, strengths, dosing schedules and inactive ingredients. Therapeutic substitution depends on product labeling, state law, payer policy and prescriber direction.

What is the most valuable excipient opportunity in an Auvelity follow-on product?

A controlled-release platform that reproduces the required pharmacokinetic and dissolution profile while enabling a smaller tablet, lower manufacturing cost or alternative dosage form has the strongest commercial potential.

References

1. U.S. Food and Drug Administration. (2022). FDA approves new oral treatment for major depressive disorder, Auvelity. https://www.fda.gov
2. U.S. Food and Drug Administration. (2022). Auvelity prescribing information. Axsome Therapeutics, Inc. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs. https://www.fda.gov
5. U.S. Food and Drug Administration. (2024). New chemical entity exclusivity. https://www.fda.gov
6. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs. https://uscode.house.gov
7. Federal Trade Commission. (2024). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act. https://www.ftc.gov
8. Axsome Therapeutics, Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission. https://www.sec.gov